Gilead Sciences, Inc. vs National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares — how do they compare? Gilead Sciences, Inc. trades at $155.08 (market cap $183.41B), while National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.82 (market cap $78.25B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays the higher dividend (4.14%). Which is the better fit depends on your goals.
| GILD | NGG | |
|---|---|---|
Market Cap | $183.41B | $78.25B |
Volume | 5,557,651 | 1,070,031 |
Sector | Health | Utilities |
52-Week High | $155.80 | $93.93 |
52-Week Low | $117.85 | $73.54 |
Typical Hold Time | 112 Days | — |
Enterprise Value | $206.48B | $136.28B |
Dividend Yield | 2.22% | 4.14% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $153.54, up 2.07% today, near its consensus price target of $153.13. The stock shows a bullish technical trend with strong moving average signals. Recent earnings beat expectations in Q2 2026, though the company posted a net loss. Revenue growth is steady, with 2025 revenue at $29.44B, but profitability metrics like ROE and net income margin are negative. Positive news includes expanded HIV drug access in Latin America.
The outlook is mixed: analyst consensus is bullish with 65.52% buy ratings, but high debt and negative margins pose risks. Key catalysts include oncology pipeline advances and HIV franchise growth, while execution risks and competitive pressures remain concerns for investors.
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →